Nebivolol and its 4-Keto Derivative Increase Nitric Oxide in Endothelial Cells by Reducing its Oxidative Inactivation

Journal of the American College of Cardiology

Volumn 42, Issue 10, 2003, Pages 1838-1844

  Cominacini, Luciano ^a,d   Pasini, Anna Fratta ^a   Garbin, Ulisse ^a   Nava, Cristina ^a   Davoli, Anna ^a   Criscuoli, Marco ^b   Crea, Attilio ^b   Sawamura, Tatsuya ^c   Cascio, Vincenzo Lo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Dept Preclin Devmt Menarini R ^*  (Italy)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; LOW DENSITY LIPOPROTEIN; MONOCLONAL ANTIBODY; NEBIVOLOL; NITRIC OXIDE; NITRITE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CATTLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM;

EID: 0242552054     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.06.011     Document Type: Article

References (40)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
2. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologie and chemical properties of nitric oxide radical. Circ Res 1987; 61:866-79.
3. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Endothelial dysfunction in hypertension. Fact or fancy? J Cardiovasc Pharmacol 1998;32 Suppl 3:S41-7.
4. Brush JE Jr, Faxon DP, Salmon S, Jacobs AK, Ryan TJ. Abnormal endothelium dependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol 1992;19:809-15.
5. Drexler H, Zeiher AM, Meisner K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet 1991;338:1546-50.
6. Van de Water A, Janssens W, Van Nauten J, Xhommeux R, de Cree J. Pharmacological and haemodynamic profile of nebivolol, a chemically novel, potent and selective β-1 adrenergic antagonist. J Cardiovasc Pharmacol 1988;11:552-63.
7. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frohlich JC. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 2000;50:377-9.
8. Gao YS, Nagao T, Bond RA. Nebivolol induces endothelium dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991;17:964-9.
9. Cockroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71.
10. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation 2001;104:511-5.
11. Broeders M, Doevendans P, Bekkers B, et al. Nebivolol: a third-generation β-blocker that augments vascular nitric oxide release. Circulation 2000;102:877-84.
12. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
13. Ignarro RJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990;30:535-60.
14. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998;97:2222-9.
15. Cominacini L, Fratta Pasini A, Garbin U, et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kB through an increase production of intracellular reactive oxygen species. J Biol Chem 2000;275: 12633-8.
16. Cominacini L, Garbin U, Fratta Pasini A, et al. Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine. J Hypertens 1998;16:1913-9.
17. Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-7.
18. Landegren U. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase: application to detection of lymphokines and cell surface antigens. J Immunol Methods 1984;67:379-85.
19. Cheymol G, Poirier JM, Carrupt PA, et al. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 1997;43:563-70.
20. Chiu FC, Zhang JN, Li RC, Raymond K. Efficient assay for the determination of atenolol in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr Biomed Sci Appl 1997;691:473-7.
21. Cominacini L, Rigoni A, Fratta Pasini A, et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 2001;276:13750-5.
22. Smith P, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;105:293-9.
23. Yamamori T, Inanami O, Sunimoto H, Akasaki T, Nagahata H, Kuwabara M. Relationship between p38 mitogen-activated protein kinase and small GTPase Rac for the activation of NADPH oxidase in bovine neutrophils. Biochem Biophys Res Commun 2002;293: 1571-8.
24. Zhou M, Diwu Z, Panchuk-Voloshina N, Haugland RP. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem 1997;253:162-8.
25. McCord JM, Fridovich I. Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969;244:6049-55.
26. Chen L, Salafranca MN, Mehta JL. Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. Am J Physiol 1997;42:1854-9.
27. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002;91:406-13.
28. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:685-94.
29. Cominacini L, Fratta Pasini A, Garbin U, et al. The platelet-endothelium interaction mediated by LOX-1 reduces the intracellular concentration of nitric oxide in endothelial cells. J Am Coll Cardiol 2003;41:499-507.
30. Babior BM. NADPH oxidase: an update. Blood 1999;93:1464-76.
31. Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002;277:19952-60.
32. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. J Biol Chem 2003;278:12094-100.
33. Li D, William V, Liu L, et al. LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation. Am J Physiol Heart Circ Physiol 2002;283:1795-801.
34. Li D, Liu L, Chen H, et al. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003;107:612-7.
35. Parenti A, Filippi S, Amerini S, et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 2000;292: 698-703.
36. Shimokawa H, Tomoike H, Nabeyama S, et al. Coronary artery spasm induced in atherosclerotic miniature swine. Science 1983;221:560-2.
37. Shimokawa H, Flavahan NA, Shepherd JT, Vanhoutte PM. Endothelium- dependent inhibition of ergonovine-induced contraction is impaired in porcine coronary arteries with regenerated endothelium. Circulation 1989;80:643-50.
38. Zou MH, Bachschmid M. Hypoxia-reoxygenation triggers coronary vasospasm in isolated bovine coronary arteries via tyrosine nitration of prostacyclin synthase. J Exp Med 1999;190:135-40.
39. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherosclerosis? J Clin Invest 2001;107:255-64.
40. Curtin JF, Donovan M, Cotter TG. Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods 2002;265:49-72.